In a report published Monday, Canaccord Genuity analyst Neil Maruoka commented that Valeant Pharmaceuticals Intl Inc VRX is "firing on all cylinders."
Valeant On Fire
Maruoka noted the company's strong fourth-quarter report that showed a "robust" base business with an "impressive" 16 percent organic revenue growth. The analyst added that Jublia was a "standout" with $54 million in sales and should easily surpass a $300 million run rate by year-end.
Other Appealing Assets
Maruoka also added that he has "long been fans" of Salix Pharmaceuticals, Ltd.'s SLXP assets and based on Valeant's due diligence, Xifaxan has a very high likelihood for FDA approval in May.
The analyst projected that Xifaxan will be an incremental $1 billion opportunity which will help contribute to a "very sustainable" longer term earnings per share growth in the double digits.
Looking Ahead
Following the fourth-quarter results and acquisition, the analyst increased his 2016 earnings per share estimates to $15.28 from $12.60, while increasing his discounted cash flow-derived price target (and maintaining a Buy rating) to $230 from a previous $183.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.